William Blair Analysts Lift Earnings Estimates for ContraFect Corporation (CFRX)
ContraFect Corporation (NASDAQ:CFRX) – Equities researchers at William Blair increased their Q3 2017 EPS estimates for ContraFect Corporation in a report issued on Wednesday. William Blair analyst Y. Xu now forecasts that the biotechnology company will earn ($0.10) per share for the quarter, up from their prior estimate of ($0.17). William Blair also issued estimates for ContraFect Corporation’s Q4 2017 earnings at ($0.09) EPS, FY2017 earnings at ($0.40) EPS and FY2018 earnings at ($0.34) EPS.
Separately, Maxim Group reiterated a “hold” rating on shares of ContraFect Corporation in a report on Thursday, May 25th.
COPYRIGHT VIOLATION WARNING: “William Blair Analysts Lift Earnings Estimates for ContraFect Corporation (CFRX)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/13/william-blair-analysts-lift-earnings-estimates-for-contrafect-corporation-cfrx.html.
Shares of ContraFect Corporation (NASDAQ:CFRX) opened at 1.25 on Friday. The company has a 50-day moving average price of $1.35 and a 200-day moving average price of $1.61. ContraFect Corporation has a 1-year low of $1.10 and a 1-year high of $3.28. The company’s market cap is $52.07 million.
ContraFect Corporation (NASDAQ:CFRX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.11.
A hedge fund recently bought a new stake in ContraFect Corporation stock. Westfield Capital Management Co. LP purchased a new position in ContraFect Corporation (NASDAQ:CFRX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 149,600 shares of the biotechnology company’s stock, valued at approximately $269,000. Westfield Capital Management Co. LP owned approximately 0.36% of ContraFect Corporation at the end of the most recent quarter. 25.25% of the stock is currently owned by hedge funds and other institutional investors.
In other ContraFect Corporation news, Director Sol J. Barer purchased 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average cost of $1.24 per share, for a total transaction of $49,600.00. Following the completion of the acquisition, the director now owns 815,933 shares of the company’s stock, valued at approximately $1,011,756.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased 50,800 shares of company stock worth $62,992 over the last quarter. 9.30% of the stock is currently owned by corporate insiders.
Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.